Subtopic Deep Dive

FGF Receptors in Disease
Research Guide

What is FGF Receptors in Disease?

FGF Receptors in Disease examines the roles of FGFR mutations, amplifications, and dysregulated signaling in pathologies including cancer and skeletal disorders.

FGFR alterations drive oncogenesis and developmental diseases through aberrant tyrosine kinase signaling. Over 10 papers in the provided list detail FGFR signaling mechanisms and disease associations, with key works like Eswarakumar et al. (2005, 1905 citations) on cellular signaling and Ornitz and Marie (2002, 897 citations) on bone diseases. Recent reviews such as Xie et al. (2020, 806 citations) link FGF/FGFR pathways to health and disease contexts.

Curated Papers

Key Challenges

Why It Matters

FGFR mutations fuel cancers like bladder and cholangiocarcinoma, enabling targeted inhibitors in precision oncology (Xie et al., 2020). In skeletal disorders, FGFR3 mutations cause achondroplasia and craniosynostosis, informing genetic therapies (Ornitz and Marie, 2002). Dysregulated FGFR signaling also contributes to phosphate disorders via FGF23 interactions (Ben-Dov et al., 2007), impacting clinical management in endocrinology and orthopedics.

Key Research Challenges

Targeting FGFR Mutations

Developing selective inhibitors for mutant FGFRs in cancer faces resistance from kinase domain alterations. Xie et al. (2020) highlight isoform-specific signaling complexities. Clinical translation requires overcoming off-target effects in diverse tumor microenvironments.

Skeletal Disorder Mechanisms

Activating FGFR3 mutations disrupt endochondral bone growth, as detailed in Ornitz and Marie (2002). Challenges persist in modeling human phenotypes in mice due to species-specific signaling differences. Therapeutic correction demands precise gain-of-function reversal without growth plate toxicity.

Signaling Pathway Crosstalk

FGFR pathways intersect with PDGF and WNT signaling in disease progression (Andræ et al., 2008; Katoh and Katoh, 2007). Eswarakumar et al. (2005) note heparin-dependent receptor specificity complicating inhibition. Quantifying network interactions hinders predictive modeling.

Essential Papers

Role of platelet-derived growth factors in physiology and medicine

Johanna Andræ, R Gallini, Christer Betsholtz · 2008 · Genes & Development · 2.4K citations

Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) have served as prototypes for growth factor and receptor tyrosine kinase function for more than 25 years. Studies of PDGFs and P...

Fibroblast growth factors.

David M. Ornitz, Nobuyuki Itoh · 2001 · Genome Biology · 1.9K citations

Cellular signaling by fibroblast growth factor receptors

Veraragavan P. Eswarakumar, Irit Lax, Joseph Schlessinger · 2005 · Cytokine & Growth Factor Reviews · 1.9K citations

Receptor Specificity of the Fibroblast Growth Factor Family

David M. Ornitz, Jian Xu, Jennifer S. Colvin et al. · 1996 · Journal of Biological Chemistry · 1.9K citations

Fibroblast growth factors (FGFs) are essential molecules for mammalian development. The nine known FGF ligands and the four signaling FGF receptors (and their alternatively spliced variants) are ex...

Fibroblast growth factors, their receptors and signaling.

Ciaran Powers, Sandra W. McLeskey, Anton Wellstein · 2000 · Endocrine Related Cancer · 1.3K citations

Fibroblast growth factors (FGFs) are small polypeptide growth factors, all of whom share in common certain structural characteristics, and most of whom bind heparin avidly. Many FGFs contain signal...

The parathyroid is a target organ for FGF23 in rats

Iddo Z. Ben‐Dov, Hillel Galitzer, Vardit Lavi-Moshayoff et al. · 2007 · Journal of Clinical Investigation · 948 citations

Phosphate homeostasis is maintained by a counterbalance between efflux from the kidney and influx from intestine and bone. FGF23 is a bone-derived phosphaturic hormone that acts on the kidney to in...

FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease

David M. Ornitz, Pierre J. Marie · 2002 · Genes & Development · 897 citations

Over the last decade the identification of mutations in the receptors for fibroblast growth factors (FGFs) has defined essential roles for FGF signaling in both endochondral and intramembranous bon...

Reading Guide

Foundational Papers

Start with Eswarakumar et al. (2005, 1905 citations) for core FGFR signaling mechanisms and Ornitz et al. (1996, 1889 citations) for receptor specificity, establishing disease context basics.

Recent Advances

Study Xie et al. (2020, 806 citations) for comprehensive FGF/FGFR roles in disease and Ben-Dov et al. (2007, 948 citations) for endocrine applications.

Core Methods

Techniques include heparin-binding assays (Ornitz et al., 1996), genetic mouse models (Ornitz and Marie, 2002), and tyrosine kinase inhibitor profiling (Powers et al., 2000).

How PapersFlow Helps You Research FGF Receptors in Disease

Discover & Search

Research Agent uses searchPapers and exaSearch to query 'FGFR mutations in cancer and skeletal diseases', retrieving Xie et al. (2020) and Ornitz and Marie (2002); citationGraph maps connections to Eswarakumar et al. (2005) for signaling insights; findSimilarPapers expands to Powers et al. (2000).

Analyze & Verify

Analysis Agent applies readPaperContent to parse FGFR mutation data from Xie et al. (2020), verifies claims with CoVe against Ornitz et al. (2001), and runs PythonAnalysis for statistical correlation of FGFR expression with disease outcomes using pandas on extracted datasets; GRADE grading scores evidence strength for inhibitor efficacy.

Synthesize & Write

Synthesis Agent detects gaps in FGFR inhibitor resistance via contradiction flagging across Xie et al. (2020) and Eswarakumar et al. (2005); Writing Agent employs latexEditText, latexSyncCitations for Ornitz and Marie (2002), and latexCompile to generate a review manuscript with exportMermaid diagrams of signaling cascades.

Use Cases

"Analyze FGFR3 mutation frequencies in achondroplasia cohorts from recent papers."

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas aggregation of mutation data from Ornitz and Marie 2002) → CSV export of prevalence stats.

"Draft LaTeX figure caption for FGFR signaling pathway in cancer."

Synthesis Agent → gap detection → Writing Agent → latexGenerateFigure + latexSyncCitations (Xie et al. 2020) + latexCompile → PDF preview of pathway diagram.

"Find GitHub repos implementing FGFR inhibitor binding models."

Research Agent → paperExtractUrls (from Powers et al. 2000) → Code Discovery → paperFindGithubRepo → githubRepoInspect → curated code list with docking simulations.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ FGFR papers via searchPapers → citationGraph → structured report on disease roles (Xie et al. 2020). DeepScan applies 7-step analysis with CoVe checkpoints to verify mutation impacts from Ornitz and Marie (2002). Theorizer generates hypotheses on FGFR-WNT crosstalk therapies from Katoh and Katoh (2007).

Try Doxa for FGF Receptors in Disease Research

Frequently Asked Questions

What defines FGF Receptors in Disease?

FGFR mutations and dysregulations drive cancer and skeletal pathologies via aberrant signaling (Xie et al., 2020; Ornitz and Marie, 2002).

What are key methods for studying FGFR in disease?

Kinase assays, mouse models of gain-of-function mutations, and inhibitor screens assess signaling (Eswarakumar et al., 2005; Powers et al., 2000).

What are pivotal papers on this topic?

Eswarakumar et al. (2005, 1905 citations) on signaling; Ornitz and Marie (2002, 897 citations) on bone diseases; Xie et al. (2020, 806 citations) on health-disease axis.